Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Robert, C.; Grob, J. J.; Stroyakovskiy, D.; Karaszewska, B.; Hauschild, A.; Levchenko, E.; Sileni, V. Chiarion; Schachter, J.; Garbe, C.; Bondarenko, I.; Gogas, H.; Mandala, M.; Haanen, J. B. A. G.; Lebbe, C.; Mackiewicz, A.; Rutkowski, P.; Nathan, P. D.; Ribas, A.; Davies, M. A.; Flaherty, K. T.; Burgess, P.; Tan, M.; Gasal, E.; Voi, M.; Schadendorf, D.; Long, G. V.

dc.contributor.author	Garbe, Claus
dc.date.accessioned	2020-03-03T09:30:52Z
dc.date.available	2020-03-03T09:30:52Z
dc.date.issued	2019
dc.identifier.issn	1533-4406
dc.identifier.uri	http://hdl.handle.net/10900/98493
dc.language.iso	en	de_DE
dc.publisher	Massachusetts Medical Soc	de_DE
dc.relation.uri	http://dx.doi.org/10.1056/NEJMoa1904059	de_DE
dc.subject.ddc	610	de_DE
dc.title	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190926111821_00226
utue.publikation.seiten	626-636	de_DE
utue.personen.roh	Robert, C.
utue.personen.roh	Grob, J. J.
utue.personen.roh	Stroyakovskiy, D.
utue.personen.roh	Karaszewska, B.
utue.personen.roh	Hauschild, A.
utue.personen.roh	Levchenko, E.
utue.personen.roh	Sileni, V. Chiarion
utue.personen.roh	Schachter, J.
utue.personen.roh	Garbe, C.
utue.personen.roh	Bondarenko, I.
utue.personen.roh	Gogas, H.
utue.personen.roh	Mandala, M.
utue.personen.roh	Haanen, J. B. A. G.
utue.personen.roh	Lebbe, C.
utue.personen.roh	Mackiewicz, A.
utue.personen.roh	Rutkowski, P.
utue.personen.roh	Nathan, P. D.
utue.personen.roh	Ribas, A.
utue.personen.roh	Davies, M. A.
utue.personen.roh	Flaherty, K. T.
utue.personen.roh	Burgess, P.
utue.personen.roh	Tan, M.
utue.personen.roh	Gasal, E.
utue.personen.roh	Voi, M.
utue.personen.roh	Schadendorf, D.
utue.personen.roh	Long, G. V.
dcterms.isPartOf.ZSTitelID	New England Journal of Medicine	de_DE
dcterms.isPartOf.ZS-Issue	7	de_DE
dcterms.isPartOf.ZS-Volume	381	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE